Caroline is founder and Chief Executive Officer of Elasmogen.

With postgraduate qualifications in both business and science, Caroline has a strong commercial, bio-partnering and biologics drug discovery/development background.  She has successfully led teams at Wyeth Inc and subsequently Pfizer Inc in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc. She is a member of the Opportunity North East Life Sciences Board, a member of the GVV board committed to investing in women’s health, is a Senior Associate for the Entrepreneurial Business School, Edinburgh and holds an honorary Professorship from Queen’s University Belfast having previously been their Entrepreneur in Residence.

She has been awarded a prestigious Royal Society of Edinburgh commercialisation Fellowship and is a doctoral graduate from the University of Aberdeen in Biochemistry and has an MBA from Robert Gordon University.

Andy is one of the founders of Elasmogen and as CTO manages the company’s extensive patent portfolio and IP strategy.

He also holds a number of Non-Exec positions in Life Science and other businesses in Scotland. Andy is part-time Professor of Medical Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen.

Since 2005 he has been a Fellow of the Royal Society of Edinburgh and until recently was VP Business.

Andy has worked with academics and companies across the world, developing biologics to a range of diagnostic and therapeutic targets including: oncology, inflammation, CNS disease and most recently Covid-19.

Andy is a graduate of St Andrews University.

Dr Savvas Neophytou is partner at Deepbridge Capital LLP where he heads up the firm’s Life Sciences business. Savvas also co-founded Acorn Partners, a joint venture between Deepbridge Capital, Alder Hey Hospital and software engineers WeAreNova.

He is a founding shareholder of a number of technology companies including Torafugu Tech and Cerneretec. Torafugu is engaged in the emerging field of data driven enablers to improve health outcomes and Cerneretec is engaged in the development of point of care diagnostics for the acute care hospital setting. He has also been CEO of Now Healthcare Group, an online doctor platform where he was part of the original team that set up Europe’s largest telehealth platform.

Prior to that Savvas had a long career in the City, working for 15 years as an investment banker and ECM at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald and Panmure Gordon. Sav holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.

Keith has been an Investor at BGF since 2015 leading investments across the North of Scotland. BGF are a £2.5bn fund supporting earlier stage and established private businesses, and smaller listed companies in the UK. 

Prior to joining BGF, Keith was an Investment Manager at Souter Investments, working primarily on investments in the transport sector.

Keith originally trained and qualified as a solicitor at Shepherd and Wedderburn and has an LLB honours degree and Diploma in Legal Practice from the University of Aberdeen.

Rod has over 30 years’ experience in the life science industry across both biotech and large pharma.

He has founded three innovative biopharmaceutical companies. As the CEO he has led VHsquared Ltd, PharmaKodex Ltd and Microscience Plc from scientific concept/start up through growth into clinical R&D businesses, raising equity financing while building enterprise value and steering their subsequent successful acquisitions by US and European biopharmaceutical companies.

Prior to this Rod held senior R&D and Commercial management positions at both Glaxo and SmithKline Beecham, heading up Business Development at Glaxo Welcome in the lead up to the formation of GSK.

He is an experienced non-executive Board director having previously held non exec roles at life science companies TdeltaS Ltd and Auralis Ltd and is a former Board member of the UK BioIndustry Association (BIA).

Rod is a graduate of London University with a B.Sc. in Pharmacology

Andy was one of the founders of Elasmogen and as CTO manages the company’s extensive patent portfolio and IP strategy.

He also holds a number of Non-Exec positions in Life Science and other businesses in Scotland. Andy is part-time Professor of Medical Biotechnology and Director of the Scottish Biologics Facility, University of Aberdeen.

Since 2005 he has been a Fellow of the Royal Society of Edinburgh and until recently was VP Business.

Andy has worked with academics and companies across the world, developing biologics to a range of diagnostic and therapeutic targets including: oncology, inflammation, CNS disease and most recently Covid-19.

Andy is a graduate of St Andrews University.

Rob brings over 25 years of drug development experience. He was VP of product development at ILC therapeutics. He was previously the Senior Director of Preclinical at MiroBio.

Before this, Robert worked at Oxford Biotherapeutics, where he was UK site head and Scientific Director leading the development of their therapeutic antibody programs in immune-oncology and oncology.